JP2006511579A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006511579A5 JP2006511579A5 JP2004563642A JP2004563642A JP2006511579A5 JP 2006511579 A5 JP2006511579 A5 JP 2006511579A5 JP 2004563642 A JP2004563642 A JP 2004563642A JP 2004563642 A JP2004563642 A JP 2004563642A JP 2006511579 A5 JP2006511579 A5 JP 2006511579A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- halo
- alkoxy
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 77
- 125000005843 halogen group Chemical group 0.000 claims 34
- 125000003545 alkoxy group Chemical group 0.000 claims 28
- 150000001875 compounds Chemical class 0.000 claims 27
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 24
- 125000003342 alkenyl group Chemical group 0.000 claims 17
- 125000000304 alkynyl group Chemical group 0.000 claims 17
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 125000001424 substituent group Chemical group 0.000 claims 17
- 230000008938 immune dysregulation Effects 0.000 claims 11
- 208000006673 asthma Diseases 0.000 claims 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 9
- -1 1H-tetrazol-5-yl Chemical group 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 208000023504 respiratory system disease Diseases 0.000 claims 5
- 201000004624 Dermatitis Diseases 0.000 claims 4
- 206010034277 Pemphigoid Diseases 0.000 claims 4
- 230000001684 chronic effect Effects 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 208000014674 injury Diseases 0.000 claims 4
- 210000000056 organ Anatomy 0.000 claims 4
- 206010018364 Glomerulonephritis Diseases 0.000 claims 3
- 206010019663 Hepatic failure Diseases 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 3
- 201000004681 Psoriasis Diseases 0.000 claims 3
- 206010046851 Uveitis Diseases 0.000 claims 3
- 206010006451 bronchitis Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 230000003779 hair growth Effects 0.000 claims 3
- 208000007903 liver failure Diseases 0.000 claims 3
- 231100000835 liver failure Toxicity 0.000 claims 3
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 3
- 201000000306 sarcoidosis Diseases 0.000 claims 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 3
- 210000001519 tissue Anatomy 0.000 claims 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000023328 Basedow disease Diseases 0.000 claims 2
- 208000009137 Behcet syndrome Diseases 0.000 claims 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 206010011831 Cytomegalovirus infection Diseases 0.000 claims 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 2
- 208000015023 Graves' disease Diseases 0.000 claims 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010029240 Neuritis Diseases 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 208000027418 Wounds and injury Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 208000010668 atopic eczema Diseases 0.000 claims 2
- 230000001363 autoimmune Effects 0.000 claims 2
- 208000000594 bullous pemphigoid Diseases 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000024908 graft versus host disease Diseases 0.000 claims 2
- 206010021198 ichthyosis Diseases 0.000 claims 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 208000023589 ischemic disease Diseases 0.000 claims 2
- 206010023332 keratitis Diseases 0.000 claims 2
- 230000000414 obstructive effect Effects 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 208000017520 skin disease Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- 230000008733 trauma Effects 0.000 claims 2
- 125000001425 triazolyl group Chemical group 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
- 125000006545 (C1-C9) alkyl group Chemical group 0.000 claims 1
- 125000001766 1,2,4-oxadiazol-3-yl group Chemical group [H]C1=NC(*)=NO1 0.000 claims 1
- BBVIDBNAYOIXOE-UHFFFAOYSA-N 1,2,4-oxadiazole Chemical group C=1N=CON=1 BBVIDBNAYOIXOE-UHFFFAOYSA-N 0.000 claims 1
- HXEIGYFSDRZEJG-UHFFFAOYSA-N 1-[5-[5-[4-(2-methylpropyl)phenyl]-1,2,4-oxadiazol-3-yl]-2,3-dihydro-1h-inden-1-yl]azetidine-3-carboxylic acid Chemical compound C1=CC(CC(C)C)=CC=C1C1=NC(C=2C=C3CCC(C3=CC=2)N2CC(C2)C(O)=O)=NO1 HXEIGYFSDRZEJG-UHFFFAOYSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 1
- 208000007788 Acute Liver Failure Diseases 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000026872 Addison Disease Diseases 0.000 claims 1
- 201000010000 Agranulocytosis Diseases 0.000 claims 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002065 Anaemia megaloblastic Diseases 0.000 claims 1
- 208000028185 Angioedema Diseases 0.000 claims 1
- 206010002660 Anoxia Diseases 0.000 claims 1
- 241000976983 Anoxia Species 0.000 claims 1
- 208000032467 Aplastic anaemia Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 206010004659 Biliary cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 206010006448 Bronchiolitis Diseases 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- HXEIGYFSDRZEJG-JOCHJYFZSA-N C1=CC(CC(C)C)=CC=C1C1=NC(C=2C=C3CC[C@H](C3=CC=2)N2CC(C2)C(O)=O)=NO1 Chemical compound C1=CC(CC(C)C)=CC=C1C1=NC(C=2C=C3CC[C@H](C3=CC=2)N2CC(C2)C(O)=O)=NO1 HXEIGYFSDRZEJG-JOCHJYFZSA-N 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 208000002177 Cataract Diseases 0.000 claims 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims 1
- 208000002691 Choroiditis Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009208 Cirrhosis alcoholic Diseases 0.000 claims 1
- 206010009657 Clostridium difficile colitis Diseases 0.000 claims 1
- 206010011224 Cough Diseases 0.000 claims 1
- 206010012335 Dependence Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 206010048768 Dermatosis Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 206010014824 Endotoxic shock Diseases 0.000 claims 1
- 206010014950 Eosinophilia Diseases 0.000 claims 1
- 206010014954 Eosinophilic fasciitis Diseases 0.000 claims 1
- 206010014989 Epidermolysis bullosa Diseases 0.000 claims 1
- 206010015150 Erythema Diseases 0.000 claims 1
- 206010015218 Erythema multiforme Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 208000024869 Goodpasture syndrome Diseases 0.000 claims 1
- 206010018687 Granulocytopenia Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 208000001204 Hashimoto Disease Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 claims 1
- 206010019799 Hepatitis viral Diseases 0.000 claims 1
- 208000005100 Herpetic Keratitis Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010020850 Hyperthyroidism Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 201000003838 Idiopathic interstitial pneumonia Diseases 0.000 claims 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 1
- 208000032571 Infant acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000002287 Keratoconus Diseases 0.000 claims 1
- 206010069698 Langerhans' cell histiocytosis Diseases 0.000 claims 1
- 208000001244 Linear IgA Bullous Dermatosis Diseases 0.000 claims 1
- 208000012309 Linear IgA disease Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000000682 Megaloblastic Anemia Diseases 0.000 claims 1
- 208000027530 Meniere disease Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 201000002481 Myositis Diseases 0.000 claims 1
- 206010051606 Necrotising colitis Diseases 0.000 claims 1
- 206010028974 Neonatal respiratory distress syndrome Diseases 0.000 claims 1
- 206010073938 Ophthalmic herpes simplex Diseases 0.000 claims 1
- 206010067472 Organising pneumonia Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 208000012896 Peritoneal disease Diseases 0.000 claims 1
- 208000031845 Pernicious anaemia Diseases 0.000 claims 1
- 206010036105 Polyneuropathy Diseases 0.000 claims 1
- 208000003971 Posterior uveitis Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 206010036790 Productive cough Diseases 0.000 claims 1
- 208000003100 Pseudomembranous Enterocolitis Diseases 0.000 claims 1
- 206010037128 Pseudomembranous colitis Diseases 0.000 claims 1
- 208000006311 Pyoderma Diseases 0.000 claims 1
- 208000033626 Renal failure acute Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 1
- 206010039705 Scleritis Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 206010048908 Seasonal allergy Diseases 0.000 claims 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 208000009359 Sezary Syndrome Diseases 0.000 claims 1
- 208000007107 Stomach Ulcer Diseases 0.000 claims 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims 1
- 208000001106 Takayasu Arteritis Diseases 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 208000024248 Vascular System injury Diseases 0.000 claims 1
- 208000012339 Vascular injury Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 230000009798 acute exacerbation Effects 0.000 claims 1
- 201000011040 acute kidney failure Diseases 0.000 claims 1
- 206010069351 acute lung injury Diseases 0.000 claims 1
- 208000012998 acute renal failure Diseases 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 230000036428 airway hyperreactivity Effects 0.000 claims 1
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 claims 1
- 239000003513 alkali Substances 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 201000009961 allergic asthma Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 231100000360 alopecia Toxicity 0.000 claims 1
- 208000004631 alopecia areata Diseases 0.000 claims 1
- 208000008445 altitude sickness Diseases 0.000 claims 1
- 230000007953 anoxia Effects 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 claims 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 1
- GFZWHAAOIVMHOI-UHFFFAOYSA-N azetidine-3-carboxylic acid Chemical compound OC(=O)C1CNC1 GFZWHAAOIVMHOI-UHFFFAOYSA-N 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 claims 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 claims 1
- 125000004623 carbolinyl group Chemical group 0.000 claims 1
- 239000004568 cement Substances 0.000 claims 1
- 230000000973 chemotherapeutic effect Effects 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 208000010247 contact dermatitis Diseases 0.000 claims 1
- 238000011109 contamination Methods 0.000 claims 1
- 201000009805 cryptogenic organizing pneumonia Diseases 0.000 claims 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 1
- 210000001750 dental cementum Anatomy 0.000 claims 1
- 230000008021 deposition Effects 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 claims 1
- 125000005436 dihydrobenzothiophenyl group Chemical group S1C(CC2=C1C=CC=C2)* 0.000 claims 1
- 125000005435 dihydrobenzoxazolyl group Chemical group O1C(NC2=C1C=CC=C2)* 0.000 claims 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 claims 1
- 125000005047 dihydroimidazolyl group Chemical group N1(CNC=C1)* 0.000 claims 1
- 125000001070 dihydroindolyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims 1
- 125000005048 dihydroisoxazolyl group Chemical group O1N(CC=C1)* 0.000 claims 1
- 125000005050 dihydrooxazolyl group Chemical group O1C(NC=C1)* 0.000 claims 1
- 125000005051 dihydropyrazinyl group Chemical group N1(CC=NC=C1)* 0.000 claims 1
- 125000005052 dihydropyrazolyl group Chemical group N1(NCC=C1)* 0.000 claims 1
- 125000004655 dihydropyridinyl group Chemical group N1(CC=CC=C1)* 0.000 claims 1
- 125000005053 dihydropyrimidinyl group Chemical group N1(CN=CC=C1)* 0.000 claims 1
- 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 claims 1
- 125000005044 dihydroquinolinyl group Chemical group N1(CC=CC2=CC=CC=C12)* 0.000 claims 1
- 125000005056 dihydrothiazolyl group Chemical group S1C(NC=C1)* 0.000 claims 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 claims 1
- 125000005058 dihydrotriazolyl group Chemical group N1(NNC=C1)* 0.000 claims 1
- 230000010339 dilation Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000428 dust Substances 0.000 claims 1
- 208000010227 enterocolitis Diseases 0.000 claims 1
- 230000007613 environmental effect Effects 0.000 claims 1
- 201000001564 eosinophilic gastroenteritis Diseases 0.000 claims 1
- 208000003401 eosinophilic granuloma Diseases 0.000 claims 1
- 231100000321 erythema Toxicity 0.000 claims 1
- 210000003743 erythrocyte Anatomy 0.000 claims 1
- 230000010437 erythropoiesis Effects 0.000 claims 1
- 208000024711 extrinsic asthma Diseases 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 201000005917 gastric ulcer Diseases 0.000 claims 1
- 210000004195 gingiva Anatomy 0.000 claims 1
- 208000007565 gingivitis Diseases 0.000 claims 1
- 206010019692 hepatic necrosis Diseases 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 claims 1
- 201000010884 herpes simplex virus keratitis Diseases 0.000 claims 1
- 229960001340 histamine Drugs 0.000 claims 1
- 230000003463 hyperproliferative effect Effects 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 230000007365 immunoregulation Effects 0.000 claims 1
- 230000004957 immunoregulator effect Effects 0.000 claims 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 201000006334 interstitial nephritis Diseases 0.000 claims 1
- 201000010659 intrinsic asthma Diseases 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 1
- 208000023569 ischemic bowel disease Diseases 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 claims 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims 1
- 125000005956 isoquinolyl group Chemical group 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 201000010666 keratoconjunctivitis Diseases 0.000 claims 1
- GWNVDXQDILPJIG-NXOLIXFESA-N leukotriene C4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O GWNVDXQDILPJIG-NXOLIXFESA-N 0.000 claims 1
- 201000011486 lichen planus Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 231100000149 liver necrosis Toxicity 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 208000008585 mastocytosis Diseases 0.000 claims 1
- 231100001016 megaloblastic anemia Toxicity 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 201000006938 muscular dystrophy Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 201000005962 mycosis fungoides Diseases 0.000 claims 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 claims 1
- 230000017074 necrotic cell death Effects 0.000 claims 1
- 208000004995 necrotizing enterocolitis Diseases 0.000 claims 1
- 201000002652 newborn respiratory distress syndrome Diseases 0.000 claims 1
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 claims 1
- 208000028169 periodontal disease Diseases 0.000 claims 1
- 230000003239 periodontal effect Effects 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 201000004338 pollen allergy Diseases 0.000 claims 1
- 201000006292 polyarteritis nodosa Diseases 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 230000007824 polyneuropathy Effects 0.000 claims 1
- 230000003658 preventing hair loss Effects 0.000 claims 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 1
- 125000005493 quinolyl group Chemical group 0.000 claims 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 238000002271 resection Methods 0.000 claims 1
- 206010038718 respiratory syncytial virus bronchiolitis Diseases 0.000 claims 1
- 230000002441 reversible effect Effects 0.000 claims 1
- 201000003068 rheumatic fever Diseases 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 231100000241 scar Toxicity 0.000 claims 1
- 208000010157 sclerosing cholangitis Diseases 0.000 claims 1
- 208000008742 seborrheic dermatitis Diseases 0.000 claims 1
- 230000035939 shock Effects 0.000 claims 1
- 208000024794 sputum Diseases 0.000 claims 1
- 210000003802 sputum Anatomy 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 claims 1
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
- 201000001862 viral hepatitis Diseases 0.000 claims 1
- 0 *[n]1nccc1 Chemical compound *[n]1nccc1 0.000 description 3
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43538102P | 2002-12-20 | 2002-12-20 | |
| PCT/US2003/040129 WO2004058149A2 (en) | 2002-12-20 | 2003-12-16 | 1-(amino)indanes and (1,2-dihydro-3-amino)-benzofurans, benzothiophenes and indoles |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006511579A JP2006511579A (ja) | 2006-04-06 |
| JP2006511579A5 true JP2006511579A5 (enExample) | 2006-10-12 |
| JP4516430B2 JP4516430B2 (ja) | 2010-08-04 |
Family
ID=32682229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004563642A Expired - Fee Related JP4516430B2 (ja) | 2002-12-20 | 2003-12-16 | １−（アミノ）インダン並びに（１，２−ジヒドロ−３−アミノ）−ベンゾフラン、ベンゾチオフェン及びインドール |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7220734B2 (enExample) |
| EP (1) | EP1581509B1 (enExample) |
| JP (1) | JP4516430B2 (enExample) |
| AT (1) | ATE496024T1 (enExample) |
| AU (1) | AU2003297232B2 (enExample) |
| CA (1) | CA2509218C (enExample) |
| DE (1) | DE60335827D1 (enExample) |
| WO (1) | WO2004058149A2 (enExample) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0413923A (pt) | 2003-08-29 | 2006-11-07 | Ono Pharmaceutical Co | composto capaz de ligar o receptor de s1p e uso farmacêutico do mesmo |
| CN1894225A (zh) * | 2003-12-17 | 2007-01-10 | 默克公司 | 作为鞘氨醇1－磷酸(内皮分化基因)受体激动剂的(3,4－二取代)丙酸酯 |
| US7781617B2 (en) | 2004-07-16 | 2010-08-24 | Kyorin Pharmaceutical Co., Ltd | Effective use method of medicaments and method of preventing expression of side effect |
| RU2007109207A (ru) | 2004-08-13 | 2008-09-20 | Прикис Фамэсьютикэлс, Инк. (US) | Соединения-модуляторы активности рецептора сфингозин-1-фосфата (варианты), фармацевтическая композиция, содержащая указанные соединения, и способ лечения нарушения, ассоциированного со сфингозин-1-фосфатом |
| EP2511262B1 (en) | 2004-10-12 | 2017-02-01 | Kyorin Pharmaceutical Co., Ltd. | Process for producing 2-amino-2-[2-[4-(3-benzyloxy-phenylthio)-2-chlorophenyl[ethyl]-1,3-propanediol hydrochloride |
| DK1650186T3 (da) * | 2004-10-22 | 2008-10-13 | Sun Pharmaceutical Ind Ltd | Nye dicarboxylsyrederivater |
| EP2371811B1 (en) | 2004-12-13 | 2014-10-08 | Ono Pharmaceutical Co., Ltd. | Azetidinecarboxylic acid derivative and medicinal use thereof |
| US20090280100A1 (en) * | 2005-02-25 | 2009-11-12 | Redox Bioscience Inc. | Preventive or Therapeutic Agent for Inflammatory Ocular-Surface Diseases |
| EP1873153B1 (en) * | 2005-04-22 | 2010-07-07 | Daiichi Sankyo Company, Limited | 3-azetidinecarboxylic acid derivatives for use as immunosuppressants |
| PT1932522E (pt) * | 2005-10-07 | 2012-06-26 | Kyorin Seiyaku Kk | Agente terapêutico para doenças do fígado contendo, como princípio activo, um derivado de 2- amino-1,3-propanodiol |
| RU2409570C2 (ru) | 2006-02-03 | 2011-01-20 | Тайсо Фармасьютикал Ко., Лтд. | Производные триазола |
| TWI389683B (zh) * | 2006-02-06 | 2013-03-21 | Kyorin Seiyaku Kk | A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient |
| EP1988081B1 (en) | 2006-02-06 | 2012-10-17 | Taisho Pharmaceutical Co., Ltd | Binding inhibitor of sphingosine-1-phosphate |
| WO2007099423A1 (en) * | 2006-03-02 | 2007-09-07 | Pfizer Products Inc. | 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists |
| TWI382984B (zh) | 2006-04-03 | 2013-01-21 | Astellas Pharma Inc | 雜環化合物 |
| US20090324581A1 (en) | 2006-05-09 | 2009-12-31 | Daiichi Sankyo Company Limited | Heteroarylamide lower carboxylic acid derivative |
| SG174028A1 (en) | 2006-08-08 | 2011-09-29 | Kyorin Seiyaku Kk | Aminophosphoric acid ester derivative and s1p receptor modulator containing the same as active ingredient |
| MY146775A (en) * | 2006-08-08 | 2012-09-28 | Kyorin Seiyaku Kk | Amino alcohol derivative and immunosuppressive agent having same as an active ingredient |
| JP2009269819A (ja) * | 2006-08-25 | 2009-11-19 | Asahi Kasei Pharma Kk | アミン化合物 |
| EP2014653A1 (en) * | 2007-06-15 | 2009-01-14 | Bioprojet | Novel dicarboxylic acid derivatives as S1P1 receptor agonists |
| PL2177512T3 (pl) | 2007-08-01 | 2012-09-28 | Taisho Pharmaceutical Co Ltd | Inhibitor wiązania S1P1 |
| EP2786993B1 (en) | 2007-08-13 | 2017-11-15 | Monsanto Technology LLC | Compositions and methods for controlling nematodes |
| US8476305B2 (en) | 2008-02-07 | 2013-07-02 | Kyorin Pharmaceutical Co., Ltd. | Therapeutic agent or prophylactic agent for inflammatory bowel disease comprising amino alcohol derivative as active ingredient |
| US20090298894A1 (en) * | 2008-04-21 | 2009-12-03 | Asahi Kasei Pharma Corporation | Amino acid compounds |
| AU2009258242B2 (en) * | 2008-05-14 | 2015-07-16 | The Scripps Research Institute | Novel modulators of sphingosine phosphate receptors |
| DK2913326T3 (da) * | 2008-05-14 | 2020-08-17 | Scripps Research Inst | Hidtil ukendte modulatorer af sphingosinphosphatreceptorer |
| KR20190004843A (ko) | 2008-07-23 | 2019-01-14 | 아레나 파마슈티칼스, 인크. | 자가면역성 및 염증성의 장애의 치료에 유용한 치환된 1,2,3,4-테트라히드로시클로펜타[ｂ]인돌-3-일)아세트산 유도체 |
| JP5726737B2 (ja) | 2008-08-27 | 2015-06-03 | アリーナ ファーマシューティカルズ， インコーポレイテッド | 自己免疫障害および免疫性障害の治療において有用なｓ１ｐ１受容体のアゴニストとしての置換三環式酸誘導体 |
| WO2010085584A1 (en) | 2009-01-23 | 2010-07-29 | Bristol-Myers Squibb Company | Pyrazole-i, 2, 4 -oxad iazole derivatives as s.phing0sine-1-ph0sphate agonists |
| JP2012515787A (ja) | 2009-01-23 | 2012-07-12 | ブリストル−マイヤーズ スクイブ カンパニー | 自己免疫疾患および炎症性疾患の処置におけるｓ１ｐアゴニストとしての置換オキサジアゾール誘導体 |
| WO2010085582A1 (en) | 2009-01-23 | 2010-07-29 | Bristol-Myers Squibb Company | Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases |
| US8399451B2 (en) | 2009-08-07 | 2013-03-19 | Bristol-Myers Squibb Company | Heterocyclic compounds |
| AU2010319982B2 (en) * | 2009-11-13 | 2016-02-04 | Receptos Llc | Selective heterocyclic sphingosine 1 phosphate receptor modulators |
| RS57070B1 (sr) * | 2009-11-13 | 2018-06-29 | Celgene Int Ii Sarl | Modulatori sfingozin 1 fosfatnog receptora i postupci asimetričnih sinteza |
| RS61829B1 (sr) * | 2009-11-13 | 2021-06-30 | Receptos Llc | Selektivni modulatori receptora sfingozin 1 fosfata i metode hiralne sinteze |
| KR20120093428A (ko) | 2009-12-14 | 2012-08-22 | 메르크 파텐트 게엠베하 | 스핑고신 키나아제 저해제 |
| CN108558740B (zh) | 2010-01-27 | 2021-10-19 | 艾尼纳制药公司 | S1p1受体调节剂及其盐的制备方法 |
| CA2789480A1 (en) | 2010-03-03 | 2011-09-09 | Arena Pharmaceuticals, Inc. | Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof |
| EP2560969B1 (en) | 2010-04-23 | 2015-08-12 | Bristol-Myers Squibb Company | 4-(5-isoxazolyl or 5-pyrrazolyl-1,2,4-oxadiazol-3-yl)-mandelic acid amides as sphingosin-1-phosphate 1 receptor agonists |
| WO2012040532A1 (en) | 2010-09-24 | 2012-03-29 | Bristol-Myers Squibb Company | Substituted oxadiazole compounds and their use as s1p1 agonists |
| US9481659B2 (en) | 2011-05-13 | 2016-11-01 | Celgene International Ii Sàrl | Selective heterocyclic sphingosine 1 phosphate receptor modulators |
| PL3242666T3 (pl) | 2015-01-06 | 2025-02-17 | Arena Pharmaceuticals, Inc. | Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1 |
| HUE060476T2 (hu) | 2015-06-22 | 2023-03-28 | Arena Pharm Inc | (R)-2-(7-(4-ciklopentil-3-(trifluormetil)benziloxi)-1,2,3,4- tetrahidrociklopenta[B]indol-3-il)ecetsav kristályos L-arginin-sója S1P1 receptorral kapcsolatos rendellenességek esetén való alkalmazásra |
| WO2018151873A1 (en) | 2017-02-16 | 2018-08-23 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
| CN110545848A (zh) | 2017-02-16 | 2019-12-06 | 艾尼纳制药公司 | 用于治疗具有肠外表现的炎症性肠病的化合物和方法 |
| US12156866B2 (en) | 2018-06-06 | 2024-12-03 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
| EP3847158A1 (en) | 2018-09-06 | 2021-07-14 | Arena Pharmaceuticals, Inc. | Compounds useful in the treatment of autoimmune and inflammatory disorders |
| JP2024501257A (ja) * | 2020-12-23 | 2024-01-11 | セルジーン コーポレーション | 神経変性疾患の治療のための、インダニルを含むカルボン酸化合物 |
| JP2024522718A (ja) | 2021-06-16 | 2024-06-21 | セルジーン コーポレーション | 神経変性疾患の治療のための、カルボン酸基を含むアゼチジニル化合物 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7686891A (en) | 1990-04-05 | 1991-10-30 | American National Red Cross, The | A protein family related to immediate-early protein expressed by human endothelial cells during differentiation |
| US5585476A (en) | 1994-02-15 | 1996-12-17 | Maclennan; Alexander J. | Molecular cloning and expression of G-protein coupled receptors |
| US6495579B1 (en) * | 1996-12-02 | 2002-12-17 | Angiotech Pharmaceuticals, Inc. | Method for treating multiple sclerosis |
| US5912144A (en) | 1997-04-24 | 1999-06-15 | Incyte Pharmaceuticals, Inc. | Edg-1-receptor homolog |
| US6060272A (en) | 1997-05-07 | 2000-05-09 | Human Genome Sciences, Inc. | Human G-protein coupled receptors |
| ATE273390T1 (de) | 1997-12-30 | 2004-08-15 | Nps Allelix Corp | Säugertier edg-7 rezeptor homologen |
| AU1865499A (en) | 1997-12-30 | 1999-07-26 | Allelix Biopharmaceuticals Inc. | Identification of lysolipid receptors involved in inflammatory response |
| EP1070080A4 (en) | 1998-03-09 | 2004-12-29 | Smithkline Beecham Corp | HUMAN EDG-1c POLYNUCLEOTIDES AND POLYPEPTIDES AND THEIR APPLICATIONS |
| JP2002512016A (ja) | 1998-04-23 | 2002-04-23 | スミスクライン ビーチャム コーポレーション | Ｅｄｇファミリー遺伝子、ヒトｈ２１８ |
| US6130067A (en) | 1998-05-20 | 2000-10-10 | Smithkline Beecham Corporation | Human EDG3sb gene |
| JP2002531057A (ja) | 1998-08-19 | 2002-09-24 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | Ｅｄｇ受容体ファミリーに関連したｇタンパク質結合受容体である１４２７４受容体 |
| WO2000014233A1 (en) | 1998-09-03 | 2000-03-16 | Millennium Pharmaceuticals, Inc. | 14275 receptor, a novel g-protein coupled receptor related to the edg receptor family |
| EP1112365A2 (de) | 1998-09-11 | 2001-07-04 | Max-Delbrück-Centrum Für Molekulare Medizin | Humaner un muriner g-protein gekoppelter rezeptor edg6 (endothelial differentiation gen) und seine verwendung |
| KR20080104062A (ko) | 1998-11-20 | 2008-11-28 | 아레나 파마슈티칼스, 인크. | 사람의 오르판 ｇ 단백질 커플링 수용체 |
| US6812335B1 (en) | 1999-03-23 | 2004-11-02 | The Regents Of The University Of California | Human polypeptide receptors for lysophospholipids and sphingolipids and nucleic acids encoding the same |
| WO2000060056A1 (en) | 1999-04-05 | 2000-10-12 | Smithkline Beecham Corporation | Mouse edg5 gene |
| US6323333B1 (en) | 1999-04-05 | 2001-11-27 | Smithkline Beecham Corporation | Mouse EDG1 |
| EP1172361A4 (en) | 1999-04-19 | 2002-05-08 | Shionogi & Co | SULFONAMIDE DERIVATIVES HAVING OXADIAZOLE CORES |
| WO2001004139A2 (en) | 1999-07-13 | 2001-01-18 | Smithkline Beecham Corporation | Human axor29 receptor |
| SE9902763D0 (sv) | 1999-07-21 | 1999-07-21 | Astra Pharma Inc | Novel receptor |
| WO2001011022A1 (en) | 1999-08-05 | 2001-02-15 | Smithkline Beecham Corporation | Mouse g-protein coupled receptor edg3 |
| GB9923890D0 (en) | 1999-10-08 | 1999-12-08 | Pfizer Ltd | Novel polypeptide |
| WO2001027137A2 (en) | 1999-10-12 | 2001-04-19 | Smithkline Beecham Corporation | Rattus norvegicus (edg3) |
| WO2002059081A2 (en) * | 2001-01-26 | 2002-08-01 | Kirin Beer Kabushiki Kaisha | Urea derivatives as inhibitors of ccr-3 receptor |
| ATE441654T1 (de) * | 2002-01-18 | 2009-09-15 | Merck & Co Inc | Edg-rezeptoragonisten |
| US20050070506A1 (en) | 2002-01-18 | 2005-03-31 | Doherty George A. | Selective s1p1/edg1 receptor agonists |
| AU2003202994B2 (en) * | 2002-01-18 | 2007-11-22 | Merck Sharp & Dohme Corp. | N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as Edg receptor agonists |
| AU2003217764A1 (en) | 2002-03-01 | 2003-09-16 | Merck & Co., Inc. | Aminoalkylphosphonates and related compounds as edg receptor agonists |
| EP1482896A4 (en) | 2002-03-01 | 2005-11-23 | Merck & Co Inc | AMINO ALKYL PHOSPHONATES AND RELATED COMPOUNDS AS EDG RECEPTOR AGONISTS |
| EP1549640A4 (en) | 2002-06-17 | 2008-08-06 | Merck & Co Inc | 1 - ((5-ARYL-1,2,4-OXADIAZOL-3-YL) BENZYL) AZETIDINE-3-CARBOXYLATE AND 1 - ((5-ARYL-1,2,4-OXADIAZOL-3-YL) BENZYL) PYRROLIDIN-3-CARBOXYLATE AS EDG RECEPTOR AGONISTS |
-
2003
- 2003-12-16 CA CA2509218A patent/CA2509218C/en not_active Expired - Fee Related
- 2003-12-16 JP JP2004563642A patent/JP4516430B2/ja not_active Expired - Fee Related
- 2003-12-16 AT AT03814075T patent/ATE496024T1/de not_active IP Right Cessation
- 2003-12-16 WO PCT/US2003/040129 patent/WO2004058149A2/en not_active Ceased
- 2003-12-16 DE DE60335827T patent/DE60335827D1/de not_active Expired - Lifetime
- 2003-12-16 EP EP03814075A patent/EP1581509B1/en not_active Expired - Lifetime
- 2003-12-16 AU AU2003297232A patent/AU2003297232B2/en not_active Ceased
- 2003-12-16 US US10/536,730 patent/US7220734B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006511579A5 (enExample) | ||
| JP2006528980A5 (enExample) | ||
| CA2509218A1 (en) | 1-(amino)indanes and (1,2-dihydro-3-amino)-benzofurans, benzothiophenes and indoles as edg receptor agonists | |
| JP2008517915A5 (enExample) | ||
| JP2007515432A5 (enExample) | ||
| EP3180319B1 (en) | Novel pyridazones and triazinones for the treatment and prophylaxis of hepatitis b virus infection | |
| JP2010540593A5 (enExample) | ||
| JP6813665B2 (ja) | ４−ピリドン化合物またはその塩、それを含む医薬組成物および剤 | |
| ES2405054T3 (es) | Derivados de pirazol-1,2,4-oxadiazol como agonistas de esfingosina-1-fosfato | |
| CA2498051C (en) | Pyrimidinone derivatives as therapeutic agents against acute and chronic inflammatory, ischaemic and remodelling processes | |
| AU2012312305B2 (en) | Acyclic cyanoethylpyrazoles as janus kinase inhibitors | |
| ES2271119T3 (es) | Derivados de heterociclilalquilpiperidina, su preparacion y composiciones que contienen los mismos. | |
| ES2649475T3 (es) | Derivados de piridin-4-ilo | |
| ES2389042T3 (es) | Compuestos de piridina | |
| JP2019521142A (ja) | 感染症の治療のための新規テトラヒドロピラゾロピリジン化合物 | |
| JP2010509342A5 (enExample) | ||
| JP2009532417A5 (enExample) | ||
| TW201010997A (en) | Nicotinamide derivatives | |
| ES2533095T3 (es) | Agonistas de receptores de esfingosina-1-fosfato | |
| JPH06506450A (ja) | 喘息および呼吸器官の炎症の治療に有用なヘテロサイクリックアミン類 | |
| JP2011525192A5 (enExample) | ||
| JP2002528493A5 (enExample) | ||
| HRP20211121T1 (hr) | Supstituirani biciklični spojevi | |
| CA2475712A1 (en) | Nicotinamide derivatives useful as pde4 inhibitors | |
| CA2706991A1 (en) | Heteroaryl-substituted piperidines |